AIM ImmunoTech (AIM) vs Calidi Biotherapeutics (CLDI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AIM ImmunoTech is the larger company by market cap ($7.3 million vs $3.9 million), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AIM | CLDI |
|---|---|---|
| Share price | $0.1829 | $1.05 |
| Market cap | $7.30M | $3.86M |
| 1-day change | +1.84% | +0.96% |
| EPS (TTM) | $-2.98 | $-36.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.79 | $27.84 |
| 52-week low | $0.17 | $0.986 |
| Distance from 52-week high | -93.45% | -96.23% |
| Analyst consensus | none | — |
| Avg. price target upside | +2223.67% | — |
| Average volume | 4.70M | 255.53K |
| Shares outstanding | 39.89M | 3.68M |
| Employees | 19 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AIM ImmunoTech
AIM stock →AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
About Calidi Biotherapeutics
CLDI stock →Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 29 employees
AIM vs CLDI FAQ
Which is bigger, AIM ImmunoTech or Calidi Biotherapeutics?
AIM ImmunoTech (AIM) is larger, with a market capitalization of $7.30M compared with $3.86M for Calidi Biotherapeutics (CLDI).
Are AIM ImmunoTech and Calidi Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.